PIK3CA and melanoma: Treatment of B-RafV600E/PTEN-null melanoma cells with the B-Raf inhibitor vemurafenib led to increased fibronectin expression that abrogates the therapeutic response due to enhanced PI3K-Akt signaling and Mcl-1 expression [631].